Crossref
EE124 COST-UTILITY OF TENOFOVIR DISOPROXIL FUMARATE VERSUS ENTECAVIR FOR CHRONIC HEPATITIS B IN INDIA: A MARKOV STATE-TRANSITION MODEL
Value in Health · 2026-06 · 29 (6) · S86
DOI: 10.1016/j.jval.2026.03.419 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health, 2026-06. Verfasst von Shruthi Ashok Kumar und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Kumar, S. A., Shynu, N. E., Kumar, A. P., & GEORGE, J. (2026). EE124 COST-UTILITY OF TENOFOVIR DISOPROXIL FUMARATE VERSUS ENTECAVIR FOR CHRONIC HEPATITIS B IN INDIA: A MARKOV STATE-TRANSITION MODEL. Value in Health, 29(6), S86. https://doi.org/10.1016/j.jval.2026.03.419
Vancouver
Kumar SA, Shynu NE, Kumar AP, GEORGE J. EE124 COST-UTILITY OF TENOFOVIR DISOPROXIL FUMARATE VERSUS ENTECAVIR FOR CHRONIC HEPATITIS B IN INDIA: A MARKOV STATE-TRANSITION MODEL. Value in Health. 2026;29(6):S86. doi:10.1016/j.jval.2026.03.419
BibTeX
@article{Kumar2026,
author = {Kumar, Shruthi Ashok and Shynu, Norah E. and Kumar, Adusumilli Pramod and GEORGE, JEESA},
title = {EE124 COST-UTILITY OF TENOFOVIR DISOPROXIL FUMARATE VERSUS ENTECAVIR FOR CHRONIC HEPATITIS B IN INDIA: A MARKOV STATE-TRANSITION MODEL},
journal = {Value in Health},
year = {2026},
volume = {29},
number = {6},
pages = {S86},
doi = {10.1016/j.jval.2026.03.419}
}
EUVIMED